Urinary Tract Infections & Prostatitis (Resistance)

Key Findings

• In most cases, the disease responds well to antibiotic therapy; however, in 20-30% of patients complicated pyelonephritis develops.
• Diabetes mellitus is present in 30-35% of hospitalized patients with pyelonephritis (vs.

Key Findings

• No deaths occurred in RCTs, whereas observational studies reported 8% mortality.
• Clinical and microbiological cure exceeded 80% across study designs.

Key Findings

• Majority of the studies were from East Africa (35/44; 79.5%) whilst North Africa contributed few numbers of studies (3/44; 6.8%).
• The overall rate of uropathogens resistant to ciprofloxacin in Africa was 34% (95%, CI = 0.27-0.40) which was from isolates obtained from various study populations, including the general population (24/44; 54.5%, pregnant women (8/44; 18.1%), children (7/44; 15.9%) and HIV infected individuals (5/44; 11.4%).

Key Findings

• The pooled prevalence of HCAIs in Nigeria was 15.75% (95% CI 14.39, 17.11) and the commonest type was urinary tract infections (32.54%; 95% CI 29.44-35.64) followed by surgical site infections (22.17%; 95% CI 19.96-24.38) and skin and soft tissue infection (16.43%; 95% CI 9.42-23.43).
• The findings of this research unveil a significant prevalence of HCAIs in Nigeria, standing at 15.75%.

Key Findings

• Sixty-three studies comprising 774 499 UPEC isolates collected between 1996 and 2024 were analysed and demonstrated a global pooled prevalence of nitrofurantoin-resistant UPEC isolates to be 6.9% (95% CI: 4.8%-9.7%).
• Decade-wise subgroup analysis showed the global prevalence increased from 2.8% (1996-04) to 8.2% (2005-14) and then decreased to 7.6% in the last decade (2015-24).

Key Findings

• Bacterial eradication was significantly higher in the fosfomycin group compared to the ciprofloxacin group (OR 2.03, 95% CI 1.22-3.36, p = 0.006).
• For clinical remission, no significant difference was found in 3 studies in a total of 278 patients (OR 1.26, 95% CI 0.72-2.21, p = 0.42).

Key Findings

• In Ethiopia, the public health impact of AMR is increasingly significant, with A with improved clinical cure vs comparator and lower treatment failure.
• baumannii prevalence of 3.99% (95% CI: 3.01-4.98%) and 9.13% of all bacterial infections (95% CI: 6.73-11.54%).

Key Findings

• Particular interest is focused on evaluating the efficacy of the herbal medicinal product Canephron N in UTI prevention under conditions of rapidly increasing antibiotic resistance among uropathogenic bacterial strains, as well as the growing frequency of microbial associations and multidrug-resistant pathogens.
• Treatment efficiency and recurrence rates were evaluated for 12 months after completion of therapy.